Cargando…

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma

BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks activity of thymic stromal lymphopoietin (TSLP). In the phase IIb PATHWAY study (NCT02054130), tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) versus placebo in adults with severe, uncontrolled asthma....

Descripción completa

Detalles Bibliográficos
Autores principales:	Corren, Jonathan, Pham, Tuyet‐Hang, Garcia Gil, Esther, Sałapa, Kinga, Ren, Pin, Parnes, Jane R., Colice, Gene, Griffiths, Janet M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306691/ https://www.ncbi.nlm.nih.gov/pubmed/34913186 http://dx.doi.org/10.1111/all.15197

Ejemplares similares

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study
por: Emson, Claire, et al.
Publicado: (2021)

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
por: Corren, Jonathan, et al.
Publicado: (2021)

Targeting TSLP in Asthma
por: Parnes, Jane R, et al.
Publicado: (2022)

Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
por: Alpizar, Sady, et al.
Publicado: (2021)

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
por: Emson, Claire, et al.
Publicado: (2020)

Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
por: Menzies-Gow, Andrew, et al.
Publicado: (2023)

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma
por: Wechsler, Michael E., et al.
Publicado: (2020)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
por: Laidlaw, Tanya M, et al.
Publicado: (2023)

DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma
por: Plaza, Vicente, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects
por: Parnes, Jane R., et al.
Publicado: (2019)

Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma
por: Langley, Paul C
Publicado: (2022)

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
por: Cheng, Shih-Lung
Publicado: (2021)

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date
por: Dorey-Stein, Zachariah L, et al.
Publicado: (2021)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
por: van Dijk, Yoni E., et al.
Publicado: (2023)

The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma
por: Williams, Dennis M
Publicado: (2022)

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis
por: Zoumot, Zaid, et al.
Publicado: (2022)

The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials
por: Roy, Pooja, et al.
Publicado: (2022)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]
Publicado: (2023)

Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma
por: Lipworth, Brian, et al.
Publicado: (2023)

Tezepelumab treatment for allergic bronchopulmonary aspergillosis
por: Ogata, Hiroaki, et al.
Publicado: (2023)

Pragmatic research and outcomes in asthma and COPD
por: Colice, Gene L
Publicado: (2012)

Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis
por: Shaban Abdelgalil, Mahmoud, et al.
Publicado: (2022)

Tiotropium in asthma: a systematic review
por: Befekadu, Elizabeth, et al.
Publicado: (2014)

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials
por: Lin, Fei, et al.
Publicado: (2023)

Section 2. Exercise-Induced Bronchospasm: Albuterol versus Montelukast: Highlights of the Asthma Summit 2009: Beyond the Guidelines
por: Colice, Gene, et al.
Publicado: (2010)

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma
por: Gottlow, Mattis, et al.
Publicado: (2019)

Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2022)

Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
por: Bourdin, Arnaud, et al.
Publicado: (2020)

Mometasone furoate in the management of asthma: a review
por: Tan, Ricardo A, et al.
Publicado: (2008)

Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma
por: Carlsson, Mats, et al.
Publicado: (2019)

A Phase 1, Randomized, Placebo‐Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men
por: Sakamoto, Kei, et al.
Publicado: (2020)

Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data
por: Colice, Gene, et al.
Publicado: (2018)

Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR study
por: Franzén, Stefan, et al.
Publicado: (2016)

Exercise-induced bronchospasm: implications for patients with or without asthma in primary care practice
por: Stoloff, Stuart W, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_02agdjfl89d9naammqacqd9itn